Inhaled Treprostinil (Tyvaso Nebulizer)

Phase 2

United Therapeutics Corporation (UTHR)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

UTHRPhase 2$21.1B

Inhaled Treprostinil (Tyvaso Nebulizer) Phase 2 Est. Readout

Inhaled Treprostinil (Tyvaso Nebulizer)• COPD (Chronic Obstructive Pulmonary Disease)10

Q3 2027~QEstimated

CT.gov

00%

Competitive Landscape

0 competitors in COPD (Chronic Obstructive Pulmonary Disease)

View Full Landscape

Drug Information

Target Indication

COPD (Chronic Obstructive Pulmonary Disease)

Clinical Trial

NCT07037836

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

UTHR

United Therapeutics Corporation

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

UT-15Phase 3

Pulmonary Hypertension

Treprostinil DiolaminePhase 3

Pulmonary Arterial Hypertension

RalinepagPhase 3

Pulmonary Arterial Hypertension

Inhaled TreprostinilPhase 3

Progressive Pulmonary Fibrosis

oral treprostinilPhase 3

PAH

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts